VIDEO: Cardiovascular benefits of GLP-1 agonists ‘absolutely stunning’

BOSTON — Emerging data on the cardiovascular benefits of GLP-1 receptor agonists indicate that these agents could transform cardiovascular care, much like statins did 30 years ago, Clyde W. Yancy, MD, MSc, MACP, MACC, FAHA, FHFSA, said.

In this video, Yancy, a professor and chief of cardiology at Northwestern University Feinberg School of Medicine, discusses findings from the SELECT trial, which showed that Wegovy (semaglutide 2.4 mg, Novo Nordisk) was associated with an additional 20% RR reduction in cardiovascular events compared with placebo among patients with pre-existing heart disease.

“This is in patients who entered the trial with a previous MI, with heart failure, with hypertension, a prior stroke or peripheral vascular disease,” Yancy said. “These are the patients we see ... The results were absolutely stunning.”

This is part of a six-video Healio Video Exclusive in which Yancy recaps his talk at the ACP Internal Medicine Meeting on important updates in cardiology.

Read the full article on Yancy’s talk here and check out the other videos in this series:

• VIDEO: Newly defined syndrome is ‘a brilliant concept’ on stages of CVD risk
• VIDEO: New CVD risk algorithm incorporates social determinants of health
• VIDEO: Small interfering RNA holds promise for cardiovascular care
• VIDEO: Use incidental calcification findings to estimate CVD risk
• VIDEO: Following Life’s Essential 8 leads to ‘much better outcomes’

References:

• Lincoff AM, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2307563.
• Yancy CW. Update in cardiology. Presented at: ACP Internal Medicine Meeting; April 18-20, 2024; Boston.